{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone&page=2", "query": { "intervention": "Spironolactone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T23:09:56.317Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01488877", "title": "A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetic Nephropathy" ], "interventions": [ { "name": "PF-03882845", "type": "DRUG" }, { "name": "Spironolactone", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2012-01", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2013-10-29", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 6, "location_summary": "Chula Vista, California • San Diego, California • DeLand, Florida + 3 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01488877" }, { "nct_id": "NCT00001202", "title": "Treatment of Boys With Precocious Puberty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precocious Puberty" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Testolactone", "type": "DRUG" }, { "name": "Deslorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 80, "start_date": "1985-01", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001202" }, { "nct_id": "NCT04522739", "title": "Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Mild Cognitive Impairment", "Alzheimer Disease" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 25, "start_date": "2022-09-06", "completion_date": "2025-09-23", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04522739" }, { "nct_id": "NCT03576755", "title": "Spironolactone Therapy In Young Women With NASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NASH - Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Spironolactone 100mg", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 20, "start_date": "2019-01-09", "completion_date": "2023-07-05", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576755" }, { "nct_id": "NCT04582383", "title": "Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Doxycycline Hyclate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "16 Years to 40 Years · Female only" }, "enrollment_count": 350, "start_date": "2022-03-30", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 18, "location_summary": "Fort Smith, Arkansas • San Francisco, California • Sherman Oaks, California + 13 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04582383" }, { "nct_id": "NCT04283656", "title": "Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Transgender Health", "Gender Dysphoria", "Transgender Women", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Doravirine/Lamivudine/Tenofovir", "type": "DRUG" }, { "name": "Spironolactone 100mg", "type": "DRUG" }, { "name": "Estradiol 2mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 8, "start_date": "2022-01-04", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04283656" }, { "nct_id": "NCT02585843", "title": "Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Spironolactone 100mg", "type": "DRUG" }, { "name": "Spironolactone 25mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-11", "completion_date": "2017-03-31", "has_results": true, "last_update_posted_date": "2019-08-08", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585843" }, { "nct_id": "NCT03929718", "title": "Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "AFib" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "No Spironolactone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Piedmont Healthcare", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2019-04-24", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929718" }, { "nct_id": "NCT06205407", "title": "A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris", "type": "DRUG" }, { "name": "Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2023-12-26", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205407" }, { "nct_id": "NCT02236520", "title": "Tissue Sodium in Pre-hypertensive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Chlorthalidone", "type": "DRUG" }, { "name": "Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 71, "start_date": "2014-09", "completion_date": "2018-05-01", "has_results": true, "last_update_posted_date": "2019-05-22", "last_synced_at": "2026-09-24T23:09:56.317Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236520" } ] }